Selectivity for TP53 signalling drives the mode of action of a highly potent N,O,O-tridentate naphthoquinone-based organo-ruthenium anticancer drug candidate
- Alexander Rosner
- , Lukas Skos
- , Theresa Mendrina
- , Dina Baier-Romfeld
- , Michaela Hejl
- , Yasmin Borutzki
- , Mathias Gradl
- , Heiko Geisler
- , Thomas Mohr
- , Anton Legin
- , Michael A Jakupec
- , Andrea Bileck
- , Christopher Gerner
- , Gunda Koellensperger
- , Petra Heffeter
- , Walter Berger
- , Bernhard K Keppler
- , Wolfgang Kandioller (Korresp. Autor*in)
- , Samuel M Meier-Menches (Korresp. Autor*in)
Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed